2026 is shaping up to be a year of steady progress for biopharmaceutical innovators. While development activity remains strong, sponsors are operating in a challenging environment characterized by increasingly complex modalities, lean resourcing, regulatory uncertainty, and heightened emphasis on supply chain resilience, pushing sponsors to rethink how they develop and manufacture their assets. Several key […]

While biopharma at large faces unprecedented pressure to innovate quickly and stay competitive, small biotech organizations are particularly impacted by compressed timelines, volatile funding, and evolving regulatory demands. CDMOs play a vital role in supporting biotech sponsors through these challenges with access to expert guidance and established development and manufacturing infrastructure. Leaders from both sides

The Clinical Translation from Bench to Bedside Bringing new and innovative therapeutics to patients is a fundamental purpose of translational science. This “bench-to-beside” process is centered around harnessing knowledge gained by basic research on the bench and reducing it to, eventually, a therapeutic practice bedside. Early drug developers constantly walk a balance between getting the

Discover the role of Artificial Intelligence in revolutionizing biologics manufacturing and learn how Cytovance and partners at the University of Oklahoma are contributing to setting the new standard. Artificial Intelligence (AI) in Biomanufacturing At its core, AI involves the development of sophisticated algorithms and computational systems that can analyze vast sets of data, identify patterns

An efficient microbial strain development strategy stands as the cornerstone of expediting product development timelines and enhancing the overall product development process.